Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab ; volume:8 ; number:1 ; day:25 ; month:11 ; year:2010 ; pages:1 ; date:11.2010
Journal of translational medicine ; 8, Heft 1 (25.11.2010), 1, 11.2010
- Urheber
-
Morales-Lara, M J.
- Beteiligte Personen und Organisationen
-
Conesa-Zamora, P.
Santaclara, V.
Torres-Moreno, D.
Pedrero, F.
Moreno-Morales, J.
Cogolludo, V.
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-8-S1-P51
- URN
-
urn:nbn:de:1111-2016041436079
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Morales-Lara, M J.
- Conesa-Zamora, P.
- Santaclara, V.
- Torres-Moreno, D.
- Pedrero, F.
- Moreno-Morales, J.
- Cogolludo, V.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Body mass index influences the response to infliximab in ankylosing spondylitis
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
T-cell responses to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Body mass index influences the response to infliximab in ankylosing spondylitis
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
T-cell responses to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Body mass index influences the response to infliximab in ankylosing spondylitis
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Andersson lesion in ankylosing spondylitis
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
T cell responses to putative antigens and downregulation of cytokineproduction by infliximab in ankylosing spondylitis patients
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
T-cell response to putative antigens and downregulation of cytokine production by infliximab in ankylosing spondylitis patients